Loading
NASDAQHealthcareBiotechnology
Latest quote
$103.28
−$3.76 · -3.51%
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Latest quote
$103.28
−$3.76 · -3.51%
After-hours
$103
−$0.28 · -0.27%
Sep 10, 5:13 PM ET
Regular session · ET · Market data may be delayed.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Day range
Current $103.28
52-week range
Current $103.28
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
32
Expensive
Sentiment
58
Mixed
Risk
35
Moderate Risk
Momentum
70
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Day range
Current $103.28
52-week range
Current $103.28
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.04M USD | 6.24M USD | 2.83M USD | 6.42M USD | 1.48M USD |
| Gross profit | 2.04M USD | 6.24M USD | 2.83M USD | 6.42M USD | 1.48M USD |
| Research and development | 145.64M USD | 83.11M USD | 32.84M USD | 29.38M USD | 12.61M USD |
| Selling, general, and administrative | 34.33M USD | 24.99M USD | 18.16M USD | 6.74M USD | 1.96M USD |
| Operating expenses | 179.97M USD | 108.1M USD | 51M USD | 36.12M USD | 14.56M USD |
| Interest income | 16.12M USD | 17.37M USD | 4.76M USD | 1.15M USD | 100K USD |
| Depreciation and amortization | 428K USD | 412K USD | 355K USD | 147K USD | 2.02M USD |
| Operating income | −177.93M USD | −101.86M USD | −48.17M USD | −29.71M USD | −13.09M USD |
| Net income | −162.34M USD | −84.97M USD | −43.56M USD | −28.48M USD | −13.11M USD |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI177.02M0.01%2.3T USD0.03%$373.24-0.62%
State Street SPDR S&P Biotech ETFXBI151M1.33%11.33B USD0.35%$156.82-1.61%
iShares Russell 2000 ETFIWM128.67M0.16%80.51B USD0.19%$287.7-1.01%
Vanguard Extended Market ETFVXF49.12M0.05%93.7B USD0.05%$236.16-1.05%
iShares Russell 2000 Growth ETFIWO47.56M0.33%14.7B USD0.24%$365.67-1.42%
Vanguard Russell 2000 ETFVTWO28.39M0.16%17.4B USD0.06%$116.34-1.00%
Schwab U.S. Small-Cap ETFSCHA20.38M0.09%22.62B USD0.03%$33.65-1.32%
T. Rowe Capital Appreciation Equity ETFTCAF17.17M0.20%8.72B USD0.31%$42.10-0.68%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAT. Rowe Capital Appreciation Equity ETFTCAFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
